SARA FROELICH

H.R. 4366, Consolidated Appropriations Act of 2024, including provisions relating to health care H.R. 5027/S. 4469, Chronic Kidney Disease Improvement in Research and Treatment Act of 2023 H.R. 6860, Restore Protections for Dialysis Patients Act H.R. 7085, BIOSECURE Act S. 3558, to prohibit contracting with certain biotechnology providers, and for other purposes Implementation of P.L. 118-14, Continuing Appropriations Act, 2024 and Other Extensions Act, including provisions related to Title III, Health and Human Services. Implications of Supreme Court Decision on Marietta v. DaVita on Medicare Secondary Payer (MSP) statute and commercial group health insurance FY 2025 Appropriations for the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Implementation of P.L. 118-158, the American Relief Act of 2025, including provisions relating to health care

HR 5074/S. 4510, Kidney Patient Access to Technologically Innovative and Essential Nephrology Treatments (PATIENT) Act of 2023 Implementation of the Inflation Reduction Act of 2022, P.L. 117-169, drug pricing provisions Policy and technical issues related to the Medicare Advantage program and Medicare Part D prescription drug program Center for Medicare and Medicaid Innovation (CMMI) mandatory and voluntary demonstration programs for patients with chronic kidney disease Implementation of Executive Order 13879, Advancing American Kidney Health CMS proposed inclusion of phosphate binders in the End Stage Renal Disease (ESRD) Prospective Payment System (PPS) Implementation of the 21st Century Cures Act of 2016, P.L. 114-255, extension of Medicare Advantage to Medicare ESRD patients Proposed CY 2025 End Stage Renal Disease (ESRD) Prospective Payment System (PPS), Payment for Renal Dialysis Services Furnished to Individuals with Acute Kidney Injury (AKI), End Stage Renal Disease Quality Improvement Program (QIP), and End Stage Renal Disease Treatment Choices Model (ETC)

H.R. 4366, Consolidated Appropriations Act of 2024, including provisions relating to health care H.R. 5027/S. 4469, Chronic Kidney Disease Improvement in Research and Treatment Act of 2023 H.R. 6860, Restore Protections for Dialysis Patients Act H.R. 7085, BIOSECURE Act S. 3558, to prohibit contracting with certain biotechnology providers, and for other purposes Implementation of P.L. 118-14, Continuing Appropriations Act, 2024 and Other Extensions Act, including provisions related to Title III, Health and Human Services. Implications of Supreme Court Decision on Marietta v. DaVita on Medicare Secondary Payer (MSP) statute and commercial group health insurance FY 2025 Appropriations for the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

H.R. 4366, Consolidated Appropriations Act of 2024, including provisions relating to health care H.R. 5027, Chronic Kidney Disease Improvement in Research and Treatment Act of 2023 H.R. 6860, Restore Protections for Dialysis Patients Act H.R. 7085, BIOSECURE Act S. 3558, to prohibit contracting with certain biotechnology providers, and for other purposes Implementation of P.L. 118-14, Continuing Appropriations Act, 2024 and Other Extensions Act, including provisions related to Title III, Health and Human Services. Implications of Supreme Court Decision on Marietta v. DaVita on Medicare Secondary Payer (MSP) statute and commercial group health insurance CY 2024 Appropriations for the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

HR 5074, Kidney Patient Access to Technologically Innovative and Essential Nephrology Treatments (PATIENT) Act of 2023 Implementation of the Inflation Reduction Act of 2022, P.L. 117-169, drug pricing provisions Quality Improvement Program (QIP) in the End Stage Renal Disease (ESRD) prospective payment system (PPS) Implementation of Final CY 2024 End Stage Renal Disease (ESRD) Prospective Payment System (PPS) and Quality Improvement Program (QIP) Rule Policy and technical issues related to the Medicare Advantage program and Medicare Part D prescription drug program Center for Medicare and Medicaid Innovation (CMMI) mandatory and voluntary demonstration programs for patients with chronic kidney disease Implementation of Executive Order 13879, Advancing American Kidney Health CMS proposed inclusion of phosphate binders in the End Stage Renal Disease (ESRD) Prospective Payment System (PPS) Implementation of the 21st Century Cures Act of 2016, P.L. 114-255, extension of Medicare Advantage to Medicare ESRD patients

AKEBIA THERAPEUTICS, INC.

AKEBIA THERAPEUTICS, INC.

AKEBIA THERAPEUTICS, INC.

AKEBIA THERAPEUTICS, INC.